It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GILD’s FA Score shows that 4 FA rating(s) are green while.
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GILD’s TA Score shows that 5 TA indicator(s) are bullish.
GILD (@Pharmaceuticals: Major) experienced а +6.18% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.44%. For the same industry, the average monthly price growth was +3.00%, and the average quarterly price growth was +9.43%.
GILD is expected to report earnings on Nov 07, 2024.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
GILD | ||
---|---|---|
OUTLOOK RATING 1..100 | 95 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 22 | |
SMR RATING 1..100 | 83 | |
PRICE GROWTH RATING 1..100 | 11 | |
P/E GROWTH RATING 1..100 | 2 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GILD | MOTG | |
---|---|---|
RSI ODDS (%) | 4 days ago72% | 4 days ago82% |
Stochastic ODDS (%) | 4 days ago58% | 4 days ago67% |
Momentum ODDS (%) | 4 days ago53% | 4 days ago84% |
MACD ODDS (%) | 4 days ago67% | 4 days ago75% |
TrendWeek ODDS (%) | 4 days ago52% | 4 days ago82% |
TrendMonth ODDS (%) | 4 days ago56% | 4 days ago79% |
Advances ODDS (%) | 4 days ago54% | 4 days ago80% |
Declines ODDS (%) | 11 days ago50% | 11 days ago71% |
BollingerBands ODDS (%) | 4 days ago63% | N/A |
Aroon ODDS (%) | 4 days ago50% | 4 days ago76% |
A.I.dvisor tells us that MOTG and BAER have been poorly correlated (+14% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MOTG and BAER's prices will move in lockstep.
Ticker / NAME | Correlation To MOTG | 1D Price Change % | ||
---|---|---|---|---|
MOTG | 100% | +0.27% | ||
BAER - MOTG | 14% Poorly correlated | -5.17% | ||
GILD - MOTG | 13% Poorly correlated | +0.51% | ||
AZN - MOTG | 10% Poorly correlated | -0.87% | ||
GSK - MOTG | 9% Poorly correlated | -0.23% | ||
CMCSA - MOTG | 7% Poorly correlated | +0.61% | ||
More |